Eli Lilly: CHMP recommends migraine medication Rayvow

( – Eli Lilly shares rose more than 3% on Wall Street on Friday after the European CHMP’s favorable recommendation for Rayvow, its migraine medication.

The title is currently gaining 3.5% after taking more than 4% in the early morning.

The Committee for Medicinal Products for Human Use (CHMP), an offshoot of the European Medicines Agency (EMA), has recommended Rayvow (lasmiditan), for the treatment of migraine in adults,

In its opinion, the Committee points out that approximately 15% of the population of the European Union suffers from migraine.

Copyright © 2022 All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.




Source link -85